Instead, ACE inhibitors may be considered for use in individuals with NAFLD due to the multifactorial benefits they present where aside from regulation of blood pressure (45), ACE inhibitors have been found to reduce decompensation (46), hepatic fibrosis (47), and steatosis (48) in NAFLD and may also provide protection against CKD (49). This evidence concerns the gene ACE and steatosis.